ACHV
Achieve Life Sciences, Inc.
Set alert
6.83 USD -0.36 -5.01%
6.57 Day range 7.27
2.65 52-week range 8.53
- YTD
- +37.42%
- 1 year
- +30.34%
- Open
- 7.12
- Prev close
- 7.19
- Mkt cap
- 704.19M
- Vol
- 1.38M
- Avg vol
- 1.45M
- EPS
- -1.69
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.57
- High
- 7.27
- Forward P/E
- -3.30
- Beta
- 1.58
- Short ratio
- 23.98
- Inst. own
- 59.60%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.53
- 200-d avg
- 4.66
- 1y target
- 16.44
Key statistics
- Market cap
- 130.34M
- Enterprise value
- 93.83M
- Trailing P/E
- 0.00
- Forward P/E
- -3.30
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.16
- EPS (TTM)
- -1.12
- Beta
- 1.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -14.94M
- Total cash
- 42.91M
- Total debt
- 9.85M
- Return on equity
- -186.03%
- Shares outstanding
- 34.39M
- Short % of float
- 10.85%
- 50-day average
- 4.53
- 200-day average
- 4.66
Analyst view
Consensus: none
Price target (mean) 16.44 +140.8% upside
Now 6.83
- Target (low)
- 10.00
- Target (mean)
- 16.44
- Target (high)
- 30.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy1
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.36.
Financials — quick view
ACHV Revenue — quarterly 0
ACHV Net income — quarterly -74.77M
ACHV EPS — quarterly -0.80
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.26 | -0.36 | -0.10 | -38.46% |
| Aug 13, 2024 | Jun 1, 2024 | -0.22 | -0.25 | -0.03 | -13.64% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.26 | -0.02 | -8.33% |
| Mar 28, 2024 | Dec 1, 2023 | -0.32 | -0.26 | +0.06 | +18.75% |
| Nov 9, 2023 | Sep 1, 2023 | -0.34 | -0.34 | 0.00 | 0.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.41 | -0.43 | -0.02 | -4.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Rodman & Renshaw | init | — | Buy |
| Aug 15, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 13, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 17, 2024 | JonesTrading | init | — | Buy |
| Apr 1, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 5, 2024 | Lake Street | main | Buy | Buy |
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- achievelifesciences.com
News
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happened
- Achieve Life Sciences Appoints Benjamin Halladay CFO, Effective Oct. 5
- Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Stifel Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $18
- Achieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026
- Achieve Life Sciences: Thesis Intact, Setup Remains Constructive (Rating Downgrade)
- Achieve Life Sciences: A Funded Manufacturing Reset, Not A Broken Clinical Thesis
Your note
Sign in to keep a note on ACHV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 10, 2019 | 0 |
| BENCICH JOHN A | Chief Operating Officer | Conversion of Exercise of derivative security | Aug 17, 2020 | 141 |
| JACOBS CINDY A | Officer | Conversion of Exercise of derivative security | Aug 17, 2020 | 176 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Resources, Inc. | 11.26% | 3,871,349 | 14.67M | Sep 29, 2024 |
| Propel Bio Management, LLC | 7.13% | 2,453,092 | 9.30M | Sep 29, 2024 |
| Blackrock Inc. | 6.02% | 2,071,132 | 7.85M | Sep 29, 2024 |
| Vanguard Group Inc | 5.64% | 1,940,388 | 7.35M | Sep 29, 2024 |
| Sofinnova Investments, Inc. | 4.40% | 1,514,032 | 5.74M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.18% | 749,109 | 2.84M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 6.34% | 2,181,025 | 8.27M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.99% | 1,027,821 | 3.90M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.42% | 831,633 | 3.15M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.83% | 629,867 | 2.39M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.01% | 347,964 | 1.32M | Aug 30, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.63% | 217,845 | 825.63K | Sep 29, 2024 |